3–12 day dispatch window due to updated U.S. documentation requirements • All tariff costs covered
Table of Contents
Botulinum toxin type A products are widely used in aesthetic medicine to temporarily reduce muscle activity and soften the appearance of dynamic facial wrinkles. Among the available options, Botox and Innotox are two well-known formulations that share a similar mechanism of action but differ in several important clinical and practical aspects.
When comparing Innotox vs. Botox, factors such as formulation, composition, storage requirements, preparation, regulatory approval, and treatment considerations can all influence product selection. Understanding these differences is important for medical professionals when evaluating which product may be more appropriate for a particular treatment setting or patient. In this article, we compare Botox vs. Innotox in detail to cover all key characteristics.
| Characteristic | Innotox | Botox |
|---|---|---|
| Manufacturer + origin | Medytox (South Korea) | Allergan / AbbVie (USA) |
| Formulation | Liquid, ready-to-use, no reconstitution | Lyophilised powder, must be reconstituted with saline |
| Active ingredient | Botulinum toxin type A | OnabotulinumtoxinA (botulinum toxin type A) |
| Complexing proteins | Free of complexing proteins | Contains complexing proteins |
| Stabiliser | No human serum albumin | Human serum albumin and sodium chloride |
| Storage | Refrigerated, 2–8 °C | Refrigerated, 2–8 °C |
| Onset | Commonly reported at 2–3 days | Commonly reported at 4–7 days |
| Approval status | Korean MFDS and select markets; not FDA-approved | FDA-approved and used globally for multiple indications |
Botox and Innotox are botulinum toxin type A products used in aesthetic medicine and, depending on the product and jurisdiction, for selected therapeutic applications. Both are designed to temporarily reduce targeted muscle activity, helping improve the appearance of dynamic wrinkles and address certain conditions associated with excessive muscle contraction. Although Botox and Innotox share the same active neurotoxin type, they differ in formulation, preparation requirements, regulatory status, and other clinical characteristics. These distinctions may influence product selection, treatment planning, and day-to-day use in aesthetic practice.
In the comparison below, we examine the key differences between Innotox vs. Botox, including their composition, formulation, handling, approved uses, and practical considerations for medical professionals.
First, let’s discuss botulinum toxin formulations. Both products are based on botulinum toxin type A, a neurotoxin derived from Clostridium botulinum. Although this substance can be harmful in high amounts, it is used in carefully controlled doses for cosmetic and therapeutic treatments. The key difference lies in the additional ingredients. Innotox is formulated without human serum albumin or animal-derived components and instead uses a synthetic stabilizer. This may appeal to patients who prefer a formulation without human- or animal-derived ingredients. Botox, in comparison, contains human serum albumin and sodium chloride, which are included as part of its established formulation and stability profile.
While comparing Innotox and Botox, you may see that their mechanisms of action are rather similar. Once administered, the solution reaches the muscle’s nerve endings and temporarily blocks the signal that makes them contract, providing wrinkle reduction or relief from muscle spasms. After some time, muscles regain their mobility, which is why repeating the procedure regularly is crucial to preserve the results.
Innotox is supplied as a ready-to-use liquid, which can make preparation and administration more accessible. Since no reconstitution is required, it also helps reduce the possibility of dilution-related errors before treatment. Botox, by comparison, is provided as a freeze-dried powder and must be reconstituted with sterile saline prior to use. Because the final concentration depends on proper preparation, careful and consistent mixing is important.
Proper storage plays an important role in maintaining product quality and supporting safe aesthetic procedures. Neuromodulators must be handled appropriately throughout the entire supply chain, from transportation to storage at the clinic.
It is worth being precise here, because this is a point that is often misreported. Innotox’s liquid format removes the reconstitution step, but it does not remove the cold chain: the product is stored refrigerated at 2–8 °C, the same as Botox. The practical saving is in preparation time, not in storage conditions.
WORTH KNOWING
If room-temperature storage is what a clinic is optimising for, the product that actually offers it is Xeomin: its labelling states that unopened vials are stored at or below 25 °C and that refrigeration is not required. Neither Botox nor Innotox has that property, so claims that Innotox can simply sit at room temperature should be treated with caution.
Both types of botulinum toxin type A injections demonstrate good results with a natural-looking finish. Innotox is commonly reported to act faster, with the first signs of improvement around 2–3 days after the session, while Botox is usually described at approximately 4–7 days. Duration is more variable and depends on the treatment area, dose, muscle activity, and individual metabolism; most botulinum toxin treatments are repeated at intervals of roughly three to four months.
In the phase III trial that compared the liquid formulation with Botox for glabellar lines, improvement rates at week 4 were not significantly different between the two, and at week 16 the liquid formulation scored higher on maximum frown. No severe adverse events were recorded.
“The efficacy and safety of MT10109L were comparable to those of Botox for the management of glabellar frown lines. MT10109L provides greater convenience because it does not require dilution.” — Kim et al., Plastic and Reconstructive Surgery (2015)
Both treatments share the familiar injection-related effects, bruising among them. Innotox lacks human serum albumin, which is often described as lowering the theoretical potential for an immune response, though direct comparative data on antibody formation between the two products are limited. Botox, for its part, has decades of clinical use supporting its safety profile.
Botox has been FDA-approved in the United States for a range of cosmetic and therapeutic applications and has an extensive history of clinical use spanning several decades. Innotox, meanwhile, is approved in South Korea and certain other markets, but it has not received FDA approval for cosmetic or therapeutic use in the United States.
Because Botox is FDA-approved and has a long-established safety record in the United States, it may offer greater reassurance from both a clinical and risk-management standpoint. Using a product that is not FDA-approved for a particular indication, however, can involve additional considerations related to patient consent, recordkeeping, and local importation or regulatory requirements. Regardless of the botulinum toxin injections used, clinics should maintain appropriate storage and cold-chain procedures, reliable product tracking, properly trained injectors, and clear documentation protocols to support safe and compliant treatment practices.
WORTH KNOWING
Distant spread of toxin effect is a boxed warning that applies to botulinum toxin products as a class, not to any one brand. Patients should be told to seek immediate medical attention if they develop swallowing or breathing difficulty, or muscle weakness away from the treated area.
To sum up, Botox and Innotox share an active ingredient and a mechanism but differ in formulation, stabiliser, preparation, and regulatory standing. Innotox offers a ready-to-use liquid and a faster reported onset; Botox offers FDA approval and decades of accumulated clinical data. Storage requirements are the same for both. Neither is universally better, and their units are not interchangeable — the right choice depends on the indication, the market you practise in, and your own experience with the product.
If you are looking for a reliable supplier of Botox or Innotox, browse the botulinum toxin selection at FillerCloud, where certified specialists can order professional-use injectables at wholesale prices.
Botox is a freeze-dried powder requiring reconstitution with saline; Innotox comes ready-to-use as a liquid, which makes administration faster and removes dilution errors. Storage, however, is the same for both — refrigerated at 2–8 °C. Innotox is also formulated without human serum albumin, while Botox contains it.
Both are used for cosmetic and therapeutic indications that relax facial muscles or address muscle spasticity, and the suitable option is chosen by a medical professional. Typically they treat dynamic facial wrinkles such as glabellar and frown lines, crow’s feet, and bunny lines. Botox additionally holds approvals for chronic migraine, excessive sweating and overactive bladder; approved indications differ by product and market.
No, Innotox is not FDA-approved. It holds approval from South Korea’s Ministry of Food and Drug Safety, which is why it is used by aesthetic professionals across a number of markets. Botox, by contrast, holds extensive FDA approval. Treating with a product outside its approved market brings extra obligations around consent, documentation and importation.
There is no single correct answer — it depends on the patient and the treatment goal. Innotox may be preferred when a ready-to-use formulation and a faster reported onset are priorities. Botox may be preferred where the indication is FDA-approved and a long record of published data matters. Remember that units are product-specific and never interchangeable between brands.
Neither wins outright. Both are effective, and in the head-to-head trial for glabellar lines the liquid formulation matched Botox at week 4 with no severe adverse events. Botox brings decades of data and formal approval; Innotox brings convenience. Outcomes depend far more on the injector’s skill than on the brand, so the procedure should be performed by a licensed, experienced specialist.
You may download the form, complete it and email back to [email protected].
Or fax it at 360.768.3126
